BNT162b2 Module 3 FDA Query Responses (November 2020)
| Author | Pfizer / BioNTech |
|---|---|
| Published | November 20, 2020 |
| Format | Report |
TL;DR — Pfizer-BioNTech regulatory sections, carrying Pfizer’s internal-use markings, on manufacturing the mRNA drug substance for the BNT162b2 COVID-19 vaccine, dated November 2020.
Sections from Module 3 (quality / chemistry, manufacturing and controls) of the regulatory dossier for BNT162b2, the Pfizer-BioNTech COVID-19 vaccine, compiled as responses to FDA queries and dated November 20, 2020, weeks before US emergency authorisation. Every page carries Pfizer’s internal-use marking.
The sections cover the manufacturing process for the modified-RNA drug substance at BioNTech Mainz / Rentschler and at Pfizer Andover, the change from the clinical-trial process (“Process 1”) to the commercial-scale “Process 2,” batch definitions, process controls and yields, equipment comparisons, and process qualification.
What it is: an internal regulatory submission never published by its owners. Copies of documents like this circulated online after the December 2020 cyberattack on the European Medicines Agency; treat it as a leaked document.
Where this came from
- A copy saved in October 2026.
158 pages. A PDF copy is held in Kyle’s private archive; it is not linked or shared here.